Fibroblast growth factor-2 (FGF2) and syndecan-1 (SDC1) are potential biomarkers for putative circulating CD15+/CD30+ cells in poor outcome Hodgkin lymphoma patients

BACKGROUND: High risk, unfavorable classical Hodgkin lymphoma (cHL) includes those patients with primary refractory or early relapse, and progressive disease. To improve the availability of biomarkers for this group of patients, we investigated both tumor biopsies and peripheral blood leukocytes (PB...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Gharbaran, Rajendra, Goy, Andre, Tanaka, Takemi, Park, Jongwhan, Kim, Chris, Hasan, Nafis, Vemulapalli, Swathi, Sarojini, Sreeja, Tuluc, Madalina, Nalley, Kip, Bhattacharyya, Pritish, Pecora, Andrew, Suh, K Stephen
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2013
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC3766006/
https://ncbi.nlm.nih.gov/pubmed/23988031
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-6-62
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars